Milestone Scientific Announces Validation and Implementation of Quick Start to the CompuFlo Epidural System

Milestone Scientific, Inc.

Companies Mentioned:

Primary Exchange: AMEX
Under the Symbol: MLSS

$1.94

$0.14

7.78%


Milestone Scientific Announces Validation and Implementation of Quick Start to the CompuFlo Epidural System

Wednesday, April 15, 2020 3:00 PM

LIVINGSTON, NJ / ACCESSWIRE / April 15, 2020 / Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has validated the new "Quick Start," which has been implemented into the CompuFlo® Epidural System. The Quick Start feature simplifies and provides an alternative pathway to reduce the procedure preparation time for the CompuFlo® instrument prior to the procedure.

Leonard Osser, Interim Chief Executive Officer of Milestone Scientific, commented, "Based on broad feedback from anesthesiologists, we found it necessary to streamline the process for CompuFlo® in order to reduce the procedure time for anesthesiologists. In addition, we are exploring ways to make the use of our disposables more efficient, which we look forward to announcing in the future. Overall, the market feedback from both anesthesiologists and hospitals has been encouraging and we look forward to providing the end users with future enhancements that they desire."

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs and develops innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone's proprietary DPS Dynamic Pressure Sensing technology® is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website: www.milestonescientific.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2018. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contact:

David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: [email protected]
Tel: 212-671-1020

SOURCE: Milestone Scientific, Inc.


Subscribe to alerts from Investor Network
SHARE ARTICLE